1. Home
  2. MURA vs FENG Comparison

MURA vs FENG Comparison

Compare MURA & FENG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MURA
  • FENG
  • Stock Information
  • Founded
  • MURA 2013
  • FENG 1998
  • Country
  • MURA Ireland
  • FENG China
  • Employees
  • MURA N/A
  • FENG N/A
  • Industry
  • MURA
  • FENG Broadcasting
  • Sector
  • MURA
  • FENG Industrials
  • Exchange
  • MURA Nasdaq
  • FENG Nasdaq
  • Market Cap
  • MURA 36.0M
  • FENG 32.7M
  • IPO Year
  • MURA N/A
  • FENG 2011
  • Fundamental
  • Price
  • MURA $2.09
  • FENG $2.34
  • Analyst Decision
  • MURA Buy
  • FENG
  • Analyst Count
  • MURA 2
  • FENG 0
  • Target Price
  • MURA $6.00
  • FENG N/A
  • AVG Volume (30 Days)
  • MURA 106.1K
  • FENG 5.0K
  • Earning Date
  • MURA 11-04-2025
  • FENG 11-13-2025
  • Dividend Yield
  • MURA N/A
  • FENG N/A
  • EPS Growth
  • MURA N/A
  • FENG N/A
  • EPS
  • MURA N/A
  • FENG N/A
  • Revenue
  • MURA N/A
  • FENG $101,168,374.00
  • Revenue This Year
  • MURA N/A
  • FENG N/A
  • Revenue Next Year
  • MURA N/A
  • FENG N/A
  • P/E Ratio
  • MURA N/A
  • FENG N/A
  • Revenue Growth
  • MURA N/A
  • FENG 5.53
  • 52 Week Low
  • MURA $0.95
  • FENG $1.28
  • 52 Week High
  • MURA $4.74
  • FENG $3.65
  • Technical
  • Relative Strength Index (RSI)
  • MURA 52.55
  • FENG 42.93
  • Support Level
  • MURA $2.06
  • FENG $2.28
  • Resistance Level
  • MURA $2.10
  • FENG $2.43
  • Average True Range (ATR)
  • MURA 0.01
  • FENG 0.07
  • MACD
  • MURA 0.00
  • FENG -0.00
  • Stochastic Oscillator
  • MURA 66.67
  • FENG 64.00

About MURA Mural Oncology plc

Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.

About FENG Phoenix New Media Limited

Phoenix New Media Ltd is a media company providing premium content on an integrated platform across the internet, mobile and TV channels in China. The company organizes its operations into two main segments: Net advertising services and Paid services. It provides its content and services through three channels: ifeng.com channel, video channel, and mobile channel. The company also offers a wide range of paid services including mobile value-added services, games, and content sales. It generates the majority of its revenue from Net advertising services. Geographically, it derives revenue from China.

Share on Social Networks: